Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as clarithromycin immediate-release tablets
clarithromycin immediate-release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| clarithromycin extended-release tablets | DRUG | 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) |
| clarithromycin immediate-release tablets | DRUG | 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) |
Inclusion Criteria: * Ambulatory subject who does not require intravenous antibiotic therapy. * Subject who has a medical history of chronic bronchitis. * A history of regular medication use (\>=3 consecutive months within the past 2 years) to treat pulmonary disease. * Subject must have evidence o...
Clarithromycin immediate-release is a small molecule antibiotic formulation developed by Abbott Laboratories, which trades as ABT. It is used to treat acute bacterial exacerbation of chronic bronchitis, a bacterial infection that worsens breathing in people with chronic bronchitis. The immediate-release tablets are also known as clarithromycin immediate-release tablets.
Clarithromycin immediate-release is used to treat acute bacterial exacerbation of chronic bronchitis, a flare-up of bacterial infection in patients with chronic bronchitis. In the clinical program, it was studied in adults aged 40 years and older across the United States, Canada, and Puerto Rico. It is an antibiotic in the infectious disease therapeutic area.
Clarithromycin immediate-release is developed by Abbott Laboratories, which is listed under the ticker ABT. Abbott sponsored the clinical trial evaluating the immediate-release tablet formulation in acute bacterial exacerbation of chronic bronchitis.
Clarithromycin immediate-release has been studied in a Phase 3 clinical trial, which is now completed. The program enrolled 465 patients in a randomized, double-blind, active-controlled design. The trial compared five days of clarithromycin extended-release tablets with seven days of clarithromycin immediate-release tablets.
Clarithromycin immediate-release was evaluated in the Phase 3 trial NCT00645086, titled a comparative study of 5 days of M02-472 clarithromycin extended-release tablets to 7 days of clarithromycin immediate-release tablets for the treatment of exacerbation of chronic bronchitis. The trial is completed and enrolled 465 participants across the United States, Canada, and Puerto Rico.
Yes. Clarithromycin immediate-release and clarithromycin immediate-release tablets refer to the same product. The immediate-release tablets are the oral formulation studied in the Phase 3 trial for acute bacterial exacerbation of chronic bronchitis, and the two names are used interchangeably for this antibiotic.